Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases.
Pediatr Rheumatol Online J
; 18(1): 56, 2020 Jul 11.
Article
em En
| MEDLINE
| ID: mdl-32653009
ABSTRACT
BACKGROUND:
Hyperferritinemic syndromes are systemic inflammatory disorders characterized by a dysfunctional immune response, which leads to excessive activation of the monocyte-macrophage system with hypercytokinemia and may pursue a rapidly fatal course. CASE PRESENTATION We describe two patients of 11 and 9 years of age with hyperferritinemic syndromes, one with impending macrophage activation syndrome (MAS) and one with overt MAS, who were refractory or intolerant to conventional therapies, but improved dramatically with canakinumab.CONCLUSIONS:
Our report indicates that canakinumab may be efficacious in the management of hyperferritinemic syndromes, including MAS.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Corticosteroides
/
Linfo-Histiocitose Hemofagocítica
/
Síndrome de Ativação Macrofágica
/
Anticorpos Monoclonais Humanizados
/
Hiperferritinemia
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália